

FIG.1 IL-18 polypeptides**FIG.1A Human IL-18 polypeptide sequence**

```

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn
 1           5           10           15
Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp
          20           25           30
Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile
          35           40           45
Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile
          50           55           60
Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile
          65           70           75           80
Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys
          85           90           95
Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys
          100          105          110
Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu
          115          120          125
Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu
          130          135          140
Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp
          145          150          155

```

FIG.1B Murine IL-18 polypeptide sequence

```

Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn
 1           5           10           15
Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met
      20           25           30
Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile
      35           40           45
Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser
      50           55           60
Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile
65           70           75           80
Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser
      85           90           95
Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu
      100          105          110
Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu
      115          120          125
Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp
      130          135          140
Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser
145           150           155

```



FIG.2 In vivo tumour growth in control non Tg mice**FIG.2A - IL-18 1 μ g + vaccination with E7 + AS02****FIG.2B - IL-18 100 μ g + vaccination with E7 + AS02**



FIG.3 In vivo tumour growth in E7 Tg mice**FIG.3A - IL-18 1 μ g + vaccination with E7 + AS02****FIG.3B - IL-18 100 μ g + vaccination with E7 + AS02**

FIG.4 Antibody response and isotypic profile in control non Tg mice**FIG.4A – Antibody response**

Total Ig response (standard titers are expressed in EU/ml).



**FIG.4B – Isotypic profile**

FIG.5 Antibody response and isotypic profile in E7 Tg mice**FIG.5A – Antibody response**

Total Ig response (standard titers are expressed in EU/ml).



**FIG.5A – Isotypic profile**

FIG. 6 In vivo tumour growth in TCI Her2 therapeutic model

